Safety evaluation of execessive consumption of proteoglycan complex 80 from salmon nasal cartilage - a randomized, double blind, placebo-controlled study -

Safety evaluation of execessive consumption of proteoglycan complex 80 from salmon nasal cartilage - a randomized, double blind, placebo-controlled study - - Safety evaluation of execessive consumption of proteoglycan complex 80 from salmon nasal cartilage

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026388

Enrollment

Registered

2017-06-01

Start date

2017-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

Ingestion of supplement containing proteoglycan complex 80 for 4 weeks Ingestion of placebo without proteoglycan complex 80 for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Healthy male and female age 20 to 65 inclusive at the time of informed consent, BMI >30 inclusive. 2.Subjects who received an enough explanation of the test objectives and detail, who have consent ability, who are willing to participate with well understandings and who have signed the informed consent document.

Exclusion criteria

Exclusion criteria: 1.Subjects who have been continuously treated by medicine. 2.Subjects who have a history of renal, hepatic, cardiac, respiratory, endocrine, or other metabolic disease or who have been treated for those diseases. 3.Subjects who have been regularly used medicine (Including antiflatulent and laxative) 4.Subjects who cannot stop taking supplement/health food (Including Special Health Food, Foods with "Function Claims") 5.Subjects who declared having an allergy for component of test tablet 6.Subjects who have a past surgical history or a history of digestive disease which affects digestion. 7.Subjects who are pregnant, willing to be pregnant or breast feeding. 8.Subjects with a history of drug dependence or alcohol dependence or past history of drug dependence or alcohol dependence 9.Subjects who made a blood component donation or whole blood donation more than 200mL within 4 weeks before the test starts 10.Subjects who have shift work or night shift work. 11.Subjects who have been participated in any other food or medicine intake clinical trial, cosmetic and medicine application trial or participated in any other clinical trial within 1 month after consent obtain, or who is willing to participate. 12.Any who is judged as unsuitable to participate in this clinical trial through by principal investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
Bloodchemistry, hematology and urine analysis at 2-week, 4-week consumption and 2-week after consumption period	—

Countries

Japan

Contacts

Public ContactYoshika Komori

KSO Corporation Sales department

yoshi@kso.co.jp03-3452-7733

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026